Abstract
In this present study, we found that the use of rosuvastatin with cumulative using duration >12 months could correlate with 2.8-fold increased risk of lung cancer in women. We did not have specific comments on these results. Further prospective clinical studies of statins use are needed to elucidate this issue.
Keywords:
lung cancer; statins.
Publication types
-
Research Support, Non-U.S. Gov't
MeSH terms
-
Adult
-
Aged
-
Dyslipidemias / drug therapy
-
Female
-
Fluorobenzenes / administration & dosage
-
Fluorobenzenes / adverse effects*
-
Humans
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / administration & dosage
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors / adverse effects*
-
Logistic Models
-
Lung Neoplasms* / chemically induced
-
Lung Neoplasms* / epidemiology
-
Middle Aged
-
Pyrimidines / administration & dosage
-
Pyrimidines / adverse effects*
-
Risk Assessment
-
Risk Factors
-
Rosuvastatin Calcium
-
Sulfonamides / administration & dosage
-
Sulfonamides / adverse effects*
-
Taiwan / epidemiology
-
Time Factors
Substances
-
Fluorobenzenes
-
Hydroxymethylglutaryl-CoA Reductase Inhibitors
-
Pyrimidines
-
Sulfonamides
-
Rosuvastatin Calcium